Platelet-rich plasma

Platelet-rich plasma
Platelet-rich plasma injection into the hand
MeSHD053657

Platelet-rich plasma (PRP), also known as autologous conditioned plasma, is a concentrate of plasma protein derived from whole blood, centrifuged to remove red blood cells but retaining platelets. Though promoted for treating various medical conditions, evidence of its benefits was mixed as of 2020, showing effectiveness in certain conditions and ineffectiveness in others.[1][2][3]

As a concentrated source of blood plasma and autologous conditioned plasma, PRP contains multiple growth factors and other cytokines that can stimulate the healing of soft tissues and joints. Indications for its use include sports medicine and orthopaedics (such as acute muscle strains, tendinopathy,tendinosis, muscle-fascial injuries, and osteoarthritis,[4]) dermatology (for androgenic alopecia, wound healing, and skin rejuvenation), and even proctology (for fistula en ano[5]).[6]

Various preparation protocols exist, with the underlying principle of concentrating platelets to 3–5 times physiological levels, then injecting this concentrate into the tissue where healing is desired.[7] Beyond clinical practice, PRP has been utilized in various tissue engineering applications involving bone, cartilage, skin, and soft tissue repair. It serves as a source for the delivery of growth factors and/or cells within tissue-engineered constructs, often in combination with biomaterials. [8]

  1. ^ Xu Q, Chen J, Cheng L (July 2019). "Comparison of platelet rich plasma and corticosteroids in the management of lateral epicondylitis: A meta-analysis of randomized controlled trials". International Journal of Surgery. 67: 37–46. doi:10.1016/j.ijsu.2019.05.003. PMID 31128316.
  2. ^ Belk JW, Kraeutler MJ, Houck DA, Goodrich JA, Dragoo JL, McCarty EC (January 2021). "Platelet-Rich Plasma Versus Hyaluronic Acid for Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials". The American Journal of Sports Medicine. 49 (1): 249–260. doi:10.1177/0363546520909397. PMID 32302218. S2CID 215809299.
  3. ^ Hurley ET, Hannon CP, Pauzenberger L, Fat DL, Moran CJ, Mullett H (May 2019). "Nonoperative Treatment of Rotator Cuff Disease With Platelet-Rich Plasma: A Systematic Review of Randomized Controlled Trials". Arthroscopy. 35 (5): 1584–1591. doi:10.1016/j.arthro.2018.10.115. PMID 31000394. S2CID 122575307.
  4. ^ Smith PA (April 2016). "Intra-articular Autologous Conditioned Plasma Injections Provide Safe and Efficacious Treatment for Knee Osteoarthritis: An FDA-Sanctioned, Randomized, Double-blind, Placebo-controlled Clinical Trial". The American Journal of Sports Medicine. 44 (4): 884–891. doi:10.1177/0363546515624678. PMID 26831629. S2CID 42338794.
  5. ^ de la Portilla F, Segura-Sampedro JJ, Reyes-Díaz ML, Maestre MV, Cabrera AM, Jimenez-Rodríguez RM, et al. (November 2017). "Treatment of transsphincteric fistula-in-ano with growth factors from autologous platelets: results of a phase II clinical trial". International Journal of Colorectal Disease. 32 (11): 1545–1550. doi:10.1007/s00384-017-2866-9. PMID 28755243. S2CID 23285036.
  6. ^ Cite error: The named reference Alves Grimalt 2017 pp. 18–24 was invoked but never defined (see the help page).
  7. ^ Cite error: The named reference prpbioactive was invoked but never defined (see the help page).
  8. ^ Lang S, Loibl M, Herrmann M (2018). "Platelet-Rich Plasma in Tissue Engineering: Hype and Hope". European Surgical Research. 59 (3–4): 265–275. doi:10.1159/000492415. PMID 30244245. S2CID 52344177.